Member Info for Matml74

Surely people aren’t believing a guy called “bigjock” who is claiming to have inside information and publishing supposed conversations with the CEO all over an anonymous BB. Are people really that stupid? FFS

brilliant news. Mining licence a formality now.

"However, I Imagine his larger shareholders will be as unimpressed as most of us here are with the mismanagement of the SP."

I am sure Conifer Management are absolutely gutted with the SP management. What a ****ing joke some people are. Filtered!

Obviously never run a business in their life. Pathetic really.

This is good news. GGP have so many shots at goal it isn't funny and in a couple of years time they will have so much cash rolling in they will be able to fund extensive exploration across their tenements. Exciting few years ahead.

Shearclass,

The poster said the company is going under. This is clearly not the case. They have added £4m since December and yes I understand the agreement completely. Will they have to return £2m of that? I highly doubt it be we will find out soon enough.

The company is an AIM stock. It is a place to raise funds if a company requires. We will find out sooner or late if that will need to be the case but people talking bull**** about the company going under should be called out.

“ Takes some time after unblinding to do the analysis, write up and submit the results, and receieve the approval.“

This is not a clinical trial where data is blinded. Everyone knows exactly what the result is on each and every test that is conducted. The PCR confirmations of the clinical samples would be lengthiest part of the process.

Des you diiick. You really should read the rns's. The second form last one will help you a lot. I will provide some little clue's for you......

"SAE is pleased to announce that it has received a second tranche investment of £2,000,000 from a subscription to be made by way of a prepayment for ordinary shares under the share placement deed, the details of which were announced to the market on 16 December 2020."

Just look at the delays coming through. Tells you all you need to know.

Bid/Ask at this time was 121/123

29-Mar-21 08:37:41 222.75 8,725 Buy* 213.00 217.00 19.43k O
29-Mar-21 08:37:19 222.75 10,000 Buy* 213.00 217.00 22.28k O
29-Mar-21 08:37:05 222.79 11,221 Buy* 213.00 217.00 25.00k O
29-Mar-21 08:37:00 222.79 10,000 Buy* 213.00 217.00 22.28k O

7% drop on no volume (200k shares traded). Typical mm games!

Prion, They could use blood samples. Nasal swabs are used early in infection as well so that makes no difference. Even my 12 year old son can do them as part of his LFD testing for school. So, I guess anyone can take a nasal swab, it is quick, and the world is now used to taking them and even doing them at home.

It is a great shame what this board has become over the past few months. In fact not just this board but I most on LSE....... Anyway here is some science for those interested.

Preprint. Precision medicine. iNF B predicts clinical outcome.

https://www.medrxiv.org/content/10.1101/2021.03.23.21253748v1

” We found that endogenous IFN-beta expression in the nasal mucosa predicts clinical outcome, independent of viral replication or Apache II score, and should be considered as a prognostic tool in a precision medicine approach of IFN therapy in COVID-19 clinical management.”

Thanks for this.

"12. PHE is continuing to work on understanding the relationship between the sensitivity
of lateral flow tests and PCR tests, and the ability to culture virus. A recent preprint1 suggests that lateral flow tests have good sensitivity in cases where virus can be cultured (i.e. those people most likely to be infectious). This supports the use of lateral flow devices to find cases which may not otherwise be identified (e.g. use for asymptomatic testing)."

Agree totally. Anyone tries to deramp put straight in bin.

All the best Paddy. Sincerest condolences to you and your family.

Early administration of INF B should work best.

https://link.springer.com/article/10.1007/s10875-021-01023-5

“ These findings suggest that the early administration of IFN-a2 or -ß, the two clinically available human type I IFNs, might be beneficial to patients with inborn errors of, or auto-Abs against type I IFN infected with SARS-CoV-2.”

“ This patient is the only known individual with neutralizing auto-Abs against type I IFNs not to have developed life-threatening pneumonia on infection with SARS-CoV-2 [1]. This observation suggests that patients with auto-Abs against IFN-a and/or IFN-?, but not against IFN-ß, could benefit from early treatment with three intramuscular injections of IFN-ß, or a single subcutaneous injection of Peg-IFN-ß, or inhaled IFN-ß [5]. Moreover, IFN-ß could also be considered in specific groups, in which the prevalence of auto-Abs is high, such as men over the age of 65 years [1].”

Well said Merc. Sean did an extensive interview on this very site a month ago. Not sure what more people want. It’s not CEO’s job to waste his time worrying about the share price. He is employed to ensure value creation within the company over the longer term. Some people should spend more time reading the exploration reports from Newcrest than these forums and they might have more confidence in their investment.

This is interesting. Perhaps 14 day treatment is not long enough.

https://www.google.co.uk/amp/s/www.news-medical.net/amp/news/20210324/SARS-CoV-2-can-cause-persistent-dendritic-cell-deficiencies.aspx

“ Dendritic cell depletion is associated with lower interferon production and poorer prognosis from SARS-CoV-2 infection, and could potentially linger for a significant period of time following recovery from COVID-19, leaving a patient vulnerable to other pathogens.”

Agent, The Microsaic's mass spectrometer is the detector. The affirmer is still needed to capture the spike protein. Doesn't effect anything related to affirmers being used in the test.

Sorry just crossed posts as I was replying to your earlier post. Seems you have worked that out!

Regarding the below. Not sure it is that simple to add the two together but what it does do is identify a means for genetic testing of covid patients to look at probabilities of progression to severe disease. There are tests being developed for this at present. I think a much larger genetic study will need to be done to work out at risk groups/ethnicities that are susceptible to these TLR genetic mutations.

It really goes back to what the great professor Holgate said in that interview in November where he was talking about precision/personalised medicine. SNG001 really can have a role to play for those with these genetic mutations that result in interferon deficiencies just like anyone who needs an asthma inhaler.